English court resumes Amgen cholesterol patent suit
The English High Court has lifted a stay on Amgen’s lawsuit which accused Sanofi-Aventis and Regeneron of infringing a patent covering pharmaceuticals which treat elevated cholesterol levels.
Roche secures rights to potential COVID-19 drug
Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
Eli Lilly’s Dermira accuses Perrigo of infringing patents
Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.
Seagen targets Daiichi in cancer drug suit
US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Abbott sues ex-employee over COVID-19 tests
Abbott Laboratories has asked an Illinois court to halt a former employee from using its name and trademarks to sell COVID-19 diagnostic tests.
WTO fails to strike deal to waive COVID-19 IP
Talks on a landmark proposal to waive IP rights for vaccines and treatments related to COVID-19 have stalled, following the failure of the World Trade Organisation to conclude an agreement.
MSD secures victory before English court
The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.
Teva withdraws Shield patent oppositions
Israeli generics company Teva has withdrawn its oppositions to two patents owned by Shield Therapeutics before the European Patent Office.
Kilpatrick Townsend hires litigation team from DLA Piper
Kilpatrick Townsend & Stockton has strengthened its life sciences expertise with the addition of a patent litigation team, that includes four litigators from DLA Piper.
Federal Circuit resuscitates Snyder’s heart valve patent
A medical device company, St. Jude Medical, part of Abbott Laboratories, failed in its bid to invalidate a patent for an artificial heart valve at the US Court of Appeals for the Federal Circuit yesterday, Thursday, October 15.
